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Abstract
Purpose To validate the hypothesis that BAK
induces low-grade inflammation in the anterior cham-
ber, we designed a study to investigate whether
switching from BAK-preserved to preservative-free
latanoprost in patients with primary open-angle glau-
coma (POAG) would reduce the flare levels.
Patients Forty-one eyes of twenty-two patients with
primary open-angle glaucoma treated with BAK-
preserved latanoprost for at least 6 months as
monotherapy were included. Exclusion criteria
included any use of topical eye drops other than
latanoprost, pseudoexfoliation and pigment dispersion
glaucoma, wearing of contact lenses and intraocular
surgery in the past year.
Methods At the start of the study, we measured
baseline flare values. We then switched all patients to
preservative-free latanoprost. After 1, 2, and
3 months, a routine ophthalmological examination
was performed and flare measurement repeated.
Results Thirty-three eyes were followed up through-
out the entire 3-month period. One month after the
switch to preservative-free latanoprost, a statistically
significant mean drop in flare of - 0.96 ph/ms
(P = 0.025) was observed. Mean flare decreased
further by- 1.31 ph/ms (P = 0.0027) after 2 months
and by - 1.25 ph/ms (P = 0.0041) after 3 months.
Conclusion The switch from BAK-preserved to
preservative-free latanoprost induced a statistically
significant reduction in mean flare value. Whereas our
previous study showed an increase in flare when
initiating treatment with BAK-preserved eye drops,
this study shows a decrease in flare upon cessation of
BAK-preserved drugs. The combined evidence from
the two studies strongly suggests that in humans BAK
exerts its effects not only on the ocular surface, but
also at the level of the anterior chamber.
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Introduction
The effect on the ocular surface of benzalkonium-
chloride (BAK), the most commonly used preserva-
tive in eye drops, has received a lot of attention over
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the past two decades. Both animal and in vitro studies
have demonstrated that BAK causes conjunctival
squamous metaplasia, apoptosis, loss of goblet cells,
breakdown of the corneal epithelial barrier, and
subclinical inflammation of the ocular surface. In fact,
chronic exposure to BAK undermines the stability of
the tear film [1]. Therefore, it comes as no surprise that
several epidemiological studies have demonstrated
that topical glaucoma treatment is a major risk factor
for the development of ocular surface disease in
glaucoma patients [2–5]. The fact that signs and
symptoms of ocular surface disease are significantly
lower in glaucoma patients using preservative-free
drops than in patients using BAK-preserved medica-
tion clearly points to the causative role BAK plays in
the genesis of this side effect [6].
If the toxic influence of BAK on the outer structures
of the eye seems to be well established by now, less is
known about the potential effect of BAK on the deeper
structures of the eye. With millions of people taking
preserved glaucoma medication daily for years or
decades, it would be highly relevant to know if there is
also a toxic effect of BAK on the inner structures of the
eye and, if present, whether it could interfere with drug
efficacy in the long run. Three in vitro studies, one on
cultured human corneal endothelial and trabecular
meshwork cells, one on human lens cell lines, and one
on human trabecular cells, demonstrated toxicity and
increased apoptotic activity related to the presence of
BAK [7–9]. The key question then is whether BAK is
able to penetrate the human eye in vivo. Up to now,
three studies addressed this issue. Myake and co-
workers investigated the effect of topical timolol and
BAK in pseudophakic patients in the early postoper-
ative period and concluded that BAK might enhance
the disruption of the blood–aqueous barrier and
increase the incidence of cystoids macular edema
[10]. More recently, another study investigated the
effect of BAK on the blood–aqueous and the blood–
retinal barrier in healthy pseudophakic patients. The
results confirmed that a short-term exposure to BAK
can cause disruption of the blood–aqueous barrier,
without altering the blood–retinal barrier. The authors
discuss the mechanism of BAK-induced subclinically
elevated flare levels and speculate that they are the
result of a low-grade inflammation caused by the
presence of BAK in the anterior chamber [11].
Finally, we showed in a previous study that
administration of BAK-preserved timolol and
preservative-free timolol both increase flare measure-
ments in the anterior chamber, but that the increase is
significantly higher in the BAK-treated eyes than in
the preservative-free-treated eyes. In that study, we
considered flare to be a proxy measure for the presence
of inflammation and concluded that BAK induces a
low-grade inflammation in the anterior chamber
analogous to what is seen in conjunctival tissue [12].
The present study was undertaken to validate the
hypothesis that BAK induces low-grade inflammation
in the anterior chamber. Whereas our first study was
designed to detect an increase in flare upon adminis-
tration of BAK, the present study was designed to
investigate whether switching from BAK-preserved to
preservative-free latanoprost in patients with open-
angle glaucoma would result in a reduction of the flare
levels.
Methods
This prospective clinical trial was approved by the
Ethics Committee of the Ghent University, and it
adhered to the tenets of the declaration of Helsinki.
Written informed consent was obtained from each
patient.
Forty-one eyes of twenty-two consecutive patients
with primary open-angle glaucoma treated with BAK-
preserved latanoprost for at least 6 months as
monotherapy were included. Exclusion criteria
included pseudoexfoliation or pigment dispersion
glaucoma, any use of topical eye drops other than
latanoprost, wearing of contact lenses, and intraocular
surgery in the past year.
At the start of the study, we measured baseline flare
values with the laser flare(-cell) meter (Kowa FM 600)
15 min after instillation of a preservative-free drop of
tropicamide. Six reliable measurements were taken,
and mean flare and SD were recorded. We then
switched all patients to preservative-free latanoprost.
After 1, 2, and 3 months, a routine ophthalmological
examination was performed and flare measurements
were repeated according to the same protocol.
The laser flare(-cell) meter is an objective, quan-
titative, noninvasive method for in vivo evaluation of
anterior segment inflammation. The instrument has
proven to be reliable and the measurements to be
reproducible. Flare intensity is proportional to counts
of aqueous proteins and is expressed as photon counts
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per milliseconds (ph/ms). Normal values for the age
groups 45–75 are in the range of 4.0–5.5 ph/ms. There
is, however, an increase in flare with age and a
decrease with pupillary dilatation [13–18]. Normal
values for the age groups 45–75 are in the range of
4.0–5.5 ph/ms [13].
Statistical methods
Sample size calculation demonstrated that for detect-
ing a 0.8 ph/ms drop in flare after 1 month (baseline
6.5 ph/ms), a total of 30 eyes were required (80%
power, 5% significance level). To assess the effect of
time, we fitted a linear mixed-effects model to the flare
values, accounting for paired eyes within patients. In
this model, patient and eye were modeled as random
effects in a nested structure. Statistical analyses were
undertaken using SAS statistical software (release
9.4).
Results
From the baseline flare values of the forty-one eyes
enrolled, two eyes were excluded because of high
baseline flare values ([ 25 ph/ms) suggestive of mild
active inflammation. At month 1, one eye was
excluded because of obvious viral keratoconjunctivi-
tis. At months 2 and 3, five eyes were lost to follow-up
because of drop-out, and these were older patients with
logistical transportation problems.
Thirty-three eyes were followed up throughout the
entire 3-month period. Figure (1) displays the mean
flare values for these thirty-three eyes at baseline and
1, 2, and 3 months after the switch. After 1 month, a
statistically significant mean drop in flare of
- 0.96 ph/ms (P = 0.025) was observed. Mean flare
decreased further by (to) - 1.31 ph/ms (P = 0.0027)
after 2 months and - 1.25 ph/ms (P = 0.0041)
3 months after the switch to preservative-free
latanoprost.
The slight increase in flare (? 0.06) at month 3
compared to month 2 was statistically not significant
(P = 0.88) indicating a stable situation with no further
decrease of the flare 2 months after the switch from
BAK-preserved to preservative-free latanoprost.
Discussion
The switch from BAK-preserved to preservative-free
latanoprost induced a statistically significant reduction
in mean flare value. This study confirms the results
from our previous work [12] and further supports our
hypothesis that BAK induces low-grade inflammation
in the anterior segment, since both preservative-free
beta-blockers and preservative-free latanoprost gen-
erate lower flare values than the BAK-preserved
drugs.
In a previous study, a randomized prospective
clinical trial, 28 previously untreated patients with
ocular hypertension were given BAK-preserved
timolol in one eye and preservative-free timolol in
the other. Baseline flare values were compared to
1-month values. Although there was an increase in
flare in both eyes, the increase was significantly higher
in the BAK-treated eye. We concluded that BAK
Fig. 1 Mean flare values
(n = thirty-three eyes) at
baseline and 1, 2, and






affects not only the outer eye but also has effects on the
anterior chamber.
The present study shows a decrease in flare upon
cessation of BAK-preserved drugs. These findings
imply two things: first, the effect of BAK on the
anterior chamber does not fade over time since it is
present in patients who received BAK-preserved drugs
for at least 6 months; and second, even after prolonged
use of BAK-preserved drugs, the effect is reversible
upon cessation of BAK. The combined evidence from
the two studies strongly suggests that in humans BAK
exerts its effects not only on the ocular surface, but
also at the level of the anterior chamber. The key
question to be answered concerns the clinical rele-
vance of this statistically significant but modest
increase of flare induced by BAK. Studies have shown
that BAK is highly cytotoxic for human trabecular
meshwork cells in vitro [8, 9].
Knowing then that BAK-preserved glaucoma med-
ications are often administered for years or decades
and that BAK is highly cytotoxic for human trabecular
meshwork cells in vitro, one might speculate that even
low concentrations of BAK contribute to the high rate
of apoptosis observed in human trabeculectomy
specimens [19]. BAK-induced toxicity at the level of
the trabecular meshwork either through apoptosis or
from low-grade inflammation could provide an alter-
native explanation for the well-known slow loss of
efficacy of glaucoma drops over time, as we discussed
in detail in a previous paper.
The fact that less patients on BAK-free travoprost
need adjunctive intraocular pressure lowering therapy
after the first-year treatment period than patients on
BAK-preserved prostaglandin analogs, as shown
recently in a retrospective study from a large phar-
macy claims database, is a case in point [20]. It could
well be that prolonged exposure (years or even
decades) to low levels of BAK in our glaucoma
patients causes progressive damage of the trabecular
meshwork, accounting for the well-known slow loss of
efficacy of topical anti-glaucoma medication over
time.
In conclusion, we demonstrated in two studies
different in design that BAK may cause an increase
in flare in the anterior chamber and this finding
justifies further research on the potential chronic
toxicity of BAK at the level of the anterior chamber
structures.
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